SOURCE: NEMUS Bioscience, Inc.

Nemus Bioscience, Inc.

May 09, 2017 08:30 ET

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

COSTA MESA, CA--(Marketwired - May 9, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that an additional United States patent has been granted covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), as well as other amide-ester forms of cannabinoid-based molecules, for use in the treatment of glaucoma. This second patent, which is also licensed to Nemus by the University of Mississippi, further expands the intellectual property (IP) estate into methods of delivery of THCVHS into the eye, by formulating the prodrug into a nanoparticle composition. This newly issued patent adds an additional 23 claims related to the delivery of the amide ester family of cannabinoids already covered in the patent previously issued to the University of Mississippi in 2015 and in-licensed by Nemus. THCVHS is the active pharmaceutical ingredient (API) in Nemus' glaucoma drug candidate known as NB1111.

"This newly issued patent related to ocular delivery of cannabinoid-based molecules further expands the IP surrounding the ophthalmology treatment platform being jointly developed by Nemus and the University," commented Brian Murphy, M.D., CEO and Chief Medical Officer of Nemus. "Our goal is to have optimized delivery of a variety of cannabinoid-based therapies into the eye providing reduced ocular pressure and a neuroprotective effect on the optic nerve and supporting structures, as in the case of glaucoma."

"The University of Mississippi has almost a half-century of experience and research into the potential therapeutic benefits of cannabinoids. We will continue our work to improve both the bio-engineering and delivery of pharmaceutical-grade cannabinoid molecules. Our research team finds the therapeutic potential against ocular diseases particularly promising given the density of cannabinoid receptors in the eye," stated Dr. Soumyajit Majumdar, associate dean for research and graduate programs and professor of pharmaceutics and drug delivery at the University of Mississippi and principal investigator on the ophthalmic projects.

"Nemus and the University plan to continue advancing cannabinoid-based therapeutic platforms in palliative care and anti-infectives, as well as ophthalmology by employing proprietary bio-engineered drug candidates that have the potential to be tailored to specific indications," said Dr. Murphy.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements about the intellectual property coverage and potential benefits of NB1111 and the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit http://www.nemusbioscience.com.

About the University of Mississippi

The University of Mississippi, the state's flagship institution, is among the elite group of R-1: Doctoral Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an Honors College acclaimed for a blend of academic rigor, experiential learning and opportunities for community action.

Contact Information

  • CONTACTS:
    NEMUS Investor Relations
    PCG Advisory Group
    Adam Holdsworth
    Email: adamh@pcgadvisory.com
    Phone: 646-862-4607

    NEMUS Media Relations
    Janet Vasquez
    JV Public Relations
    Email: jvasquez@jvprny.com
    Phone: 212.645.5498